AZ194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of NaV1.7 ( IC 50 =1.2 μM). AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed NaV1.7. Antinociceptive effects.
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Sodium Channel
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.